BioFocus DPI meets the pharma industry’s need for drug discovery tools and expertise by providing a full range of drug discovery services, from target discovery through to delivery of pre-clinical candidates. The main business areas of BioFocus DPI include informatics; biology (target discovery and screening), compound libraries, medicinal chemistry and ADMET services. BioFocus DPI currently serves more than 30 large pharmaceutical companies and biotechnology companies in Europe, North America, and Japan. With its operations in the UK, The Netherlands, Switzerland, the USA and a sales office in Japan, BioFocus DPI is well positioned to support this client base.

BioFocus DPI offers a biologically-focused discovery platform with three key differentiators - target discovery in human primary cells, targeted compound libraries and chemogenomic and ADMET informatics tools. Through a patented adenoviral based discovery platform, BioFocus DPI can rapidly identify and validate disease-modifying drug targets. Once a target has been selected, BioFocus DPI’s focused small-molecule, large diversity collection and its natural product libraries can be applied to generate “hits” – molecules with drug-like properties and activities. These hits can then be further optimized through BioFocus DPI’s expertise in medicinal and computational chemistry, as well as their assay development, high-throughput screening, and ADMET capabilities - thereby further progressing partners’ drug discovery programs.

For more information, visit the BioFocusDPI website.